为解决 实际问题而创立。
EV领域拥有非凡的潜力。所缺乏的是基础设施。我们正在构建它。
BioThera Solutions为什么要构建EV生物制造平台？
BioThera Solutions was founded to address a critical gap in the extracellular vesicle (EV/exosome) field: the absence of scalable, standardized, and reproducible manufacturing required to bring EV technologies of all kinds into real-world application. We set out to build that infrastructure as a platform, not a single product, and to lay the foundation for every application that comes after the first.
尽管越来越多的科学证据表明EV是强效的生物递送系统，但业界一直难以将实验室结果转化为商业上可行、制造一致的产品。问题不在于生物学，而在于基础设施。
We are building that infrastructure, and we started where the need was most immediate. Interest in exosome-based skincare has grown quickly, driven by genuine scientific interest and consumer demand, yet the market is crowded with products making bold claims, backed by inadequate characterization, inconsistent particle concentrations, and little regulatory transparency. There is real demand, and a real absence of material that meets rigorous scientific standards.
BioThera was built to close that gap. We bring biomanufacturing expertise to a space that has been underserved by rigorous science: characterization in line with MISEV2023, measured particle concentrations, and documentation for every batch. Our research and development has produced proprietary, patent-pending technology and the capacity to manufacture at scale. For cosmetic applications, we license our technology exclusively to Vesera™, a skincare company, and produce the material it uses.
Cosmetic applications are where the platform first meets the market, and they are only the beginning. The infrastructure we are building, from manufacturing and characterization to the evidence base, is designed to carry across biological sources and applications. Our current platform uses plant-derived vesicles; as we grow, our research extends to animal-derived sources, including human stem cell-derived vesicles, and to therapeutic applications, an important focus for our team.
Build the integrated extracellular vesicle platform the field has been missing: standardized, characterized vesicles, engineered to work across biological sources, for applications that begin with cosmetics and extend well beyond them.
With cosmetic applications as our first commercial use, we are establishing the manufacturing infrastructure, characterization rigour, and evidence base that credible EV applications, including therapeutic ones, require.
To define what credible, science-led EV technology looks like, and to build the biomanufacturing backbone the extracellular vesicle field needs to mature, across every application it reaches.
We are in the early chapters of the EV era. Our ambition is to set the standard for the field by building the manufacturing foundation, characterization rigour, and evidence base that scientists, clinicians, partners, and regulators can trust.
我们所坚守的
根本的科学透明度
我们不作无法证实的主张。每项产品规格、表征结果和监管状态都以精确的方式传达。模糊的语言和营销夸大在我们的运营方式中没有立足之地。
毫不妥协的卓越
制造标准、表征协议、配方质量，无论我们处于开发周期的哪个阶段，我们在每个环节都应用同样的严格标准。质量是内建的，而非检验出来的。
创新
EV领域还处于早期阶段。使EV在临床和商业上可行所需的制造基础设施尚不完全存在，我们正在构建它。这需要真正的科学创造力和技术勇气。
执行力
生物技术领域中创意比比皆是。严格可靠的执行却十分罕见。我们弥合科学潜力与现实世界部署之间的差距，始终如一、按时、按规格。
Ottawa, Ontario, Canada
BioThera Solutions总部位于渥太华，安大略省。我们的地理位置使我们能够接近监管机构、日益发展的生命科学生态系统以及我们工作核心的临床和研究合作者。
477-150 Louis-Pasteur Private Ottawa, Ontario K1N 6N5 Canada
渥太华大学：STEM综合楼 · Ottawa, Ontario
Company Clarification
BioThera Solutions (Canada) is an independent biotechnology firm specializing in extracellular vesicle (EV) technology. We have no affiliation with Bio-Thera Solutions, Ltd. (China), which focuses on biosimilars and antibody-drug conjugates (ADCs). Our mission is to build the integrated platform that extracellular vesicle technology requires, from research and intellectual property to manufacturing, across the sources and applications of extracellular vesicles.
ESG 与责任
BioThera Solutions operates with environmental, social, and governance (ESG) principles built into how we work. Our current vesicles are derived from medicinal plants rather than animal or human tissue, and our biomanufacturing process is designed to be scalable and resource-efficient. We are transparent about our science and communicate clearly with clinical partners, suppliers, and the broader research community. Our governance practices are aligned with Health Canada cosmetic notification requirements, and our scientific reporting follows MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines. Sustainability and ethical conduct are part of how we build for the long term.